Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling

Illumina TruSight™ Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input

Illumina's growing research and clinical oncology portfolio broadens access to critical biomarker testing

SAN DIEGO, July 30, 2025 — Illumina Inc. (NASDAQ: ILMN) today announced the launch of the next generation of TruSight Oncology 500, its flagship cancer research assay that enables comprehensive genomic profiling. Comprehensive genomic profiling (CGP) is a critical tool to accelerate access to precision medicine by providing a molecular tumor profile to labs advancing research in therapy selection and clinical trial eligibility. TruSight Oncology 500 version 2 (TSO 500 v2) offers a streamlined sample-to-analysis workflow and reflects Illumina's commitment to serving customers with the highest quality and most rigorously tested solutions.

Learn how researchers at the Catalan Institute of Oncology are using TruSight Oncology 500 v2 to streamline their workflow and accelerate their research. In this video, scientists from the institute talk about the improved assay and share how faster results help drive discovery.

This is the section for extra SEO content!

Speed

Speed

Illumina launches new, enhanced version of its flagship cancer research assay, TruSight Oncology 500v2, which enables comprehensive genomic profiling (CGP). By providing a molecular tumor profile, labs can advance research in therapy selection and clinical trial eligibility.